Modulation of Brain Oscillations Underlying Working Memory
NCT ID: NCT05923606
Last Updated: 2026-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
32 participants
INTERVENTIONAL
2024-07-10
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Criticality, Working Memory, and Effort
NCT05797636
Effect of Cross Frequency tACS on Cognitive Control
NCT03800030
Theta Connectivity in Working Memory
NCT05204381
Measuring the Latency Connectome in the Central Nervous Systems Using Neuroimaging and Neurophysiological Techniques
NCT03223636
Effects of Gamma-tACS on EEG Periodic Activity
NCT05809076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Theta-nested gamma tACS applied during passive task epochs
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during fixation periods between consecutive task trials. EEG will be acquired before and immediately after the intervention.
Active tACS
Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Theta-nested gamma tACS applied during memory delays
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. EEG will be acquired before and immediately after the intervention.
Active tACS
Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Gamma tACS applied during memory delays
Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. The stimulation will be phase locked to the peaks of ongoing theta rhythms of the participant. EEG will be acquired before and immediately after the intervention.
Active tACS
Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Placebo tACS applied during task performance
Participants will receive single-session administration of placebo tACS during performance of a working memory task. EEG will be acquired before and immediately after the intervention.
Placebo tACS
Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active tACS
Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Placebo tACS
Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent in English.
Exclusion Criteria
* Current use of psychotropic medications
* Current use of substances and drugs that were shown to affect tES (transcranial electrical stimulation) efficacy (dopamine altering drugs, nicotine, NMDA (N-methyl-D-aspartate) antagonists/agonists, sodium/calcium channel blockers, norepinephrine reuptake inhibitors, GABAergic modulators and selective serotonin reuptake inhibitors)
* Contraindications for tACS (e.g., history of seizures, metallic implants in the head or neck, implanted brain stimulators, vagus nerve stimulators, pacemakers, pregnancy)
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hamdi Eryilmaz, PhD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hamdi Eryilmaz, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Martinos Center for Biomedical Imaging
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alexandra O'Neill, B.S.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023P001479
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.